Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference
December 03 2019 - 7:00AM
Baudax Bio, Inc., (NASDAQ:BXRX) a pharmaceutical company focused on
advancing non-opioid analgesics and other products for the hospital
and other acute care settings, today announced that Gerri Henwood,
the Company’s President and Chief Executive Officer, will present
at the Piper Jaffray 31st Annual Healthcare Conference on Thursday,
December 5, 2019 at 12:00 p.m. ET at the Lotte New York Palace.
A live and archived webcast of the Piper Jaffray
presentation will be available on the Events page of the company’s
website at https://www.baudaxbio.com/. The webcast will be archived
for a period of 30 days following the conclusion of the live
event.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on therapeutics for acute care settings. The Company’s lead
product candidate is a proprietary intravenous (IV) form of
meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor.
IV meloxicam has successfully completed two pivotal Phase III
clinical efficacy trials, a large double-blind placebo-controlled
Phase III safety trial, four Phase II clinical efficacy trials, as
well as other safety studies. Upon IV meloxicam approval, ANJESOTM,
will be a novel non-opioid option for the management of moderate to
severe pain. As a non-opioid, IV meloxicam has the potential
to overcome many of the issues associated with commonly prescribed
opioid therapeutics, including respiratory depression,
constipation, excessive nausea and vomiting, as well as having no
addictive potential while maintaining meaningful analgesic effects
for relief of pain. For more information please visit
www.baudaxbio.com.
Cautionary Statement Regarding Forward
Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Baudax Bio's expectations about
its future performance and opportunities that involve substantial
risks and uncertainties. When used herein, the words "anticipate,"
"believe," "estimate," "may," "upcoming," "plan," "target,"
"intend" and "expect" and similar expressions, as they relate to
Baudax Bio or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information available to Baudax Bio as of the date of this
press release and are subject to a number of risks, uncertainties,
and other factors that could cause Baudax Bio’s performance to
differ materially from those expressed in, or implied by, these
forward-looking statements. Baudax Bio assumes no obligation to
update any such forward-looking statements. Factors that could
cause Baudax Bio’s actual performance to materially differ from
those expressed in the forward-looking statements set forth in this
press release include, without limitation: the Company’s ability to
execute its strategy for further development and commercialization
of IV meloxicam, the Company’s ability to execute its strategic
initiatives, the Company’s ability to adequately resolve the
outstanding labeling issues with the FDA for IV meloxicam, and the
time frame associated with any such resolution; the Company’s
ability to raise future financing for continued product development
and IV meloxicam commercialization; with regard to the Company’s
clinical trial results, whether there may be changes in the
interpretation by the FDA of the data of the Company’s clinical
trials and the length, cost and uncertain results and timing of our
ongoing clinical trials; with regard to the potential commercial
opportunity of IV meloxicam, whether any FDA approval of IV
meloxicam will include labeling restrictions and the potential that
IV meloxicam does not receive regulatory approval or does not
receive reimbursement by third party payors, that IV meloxicam is
not accepted by the medical community, including physicians,
patients, health care providers and hospital formularies or that a
commercial market for IV meloxicam does not develop; the Company’s
ability to manage costs and execute on its operational and budget
plans; the Company’s ability to achieve its financial goals; the
Company’s ability to obtain, maintain and successfully enforce
adequate patent and other intellectual property protection; the
Company’s lack of operating history as a standalone business; risks
relating to the separation from Recro, including, among others,
failure to achieve the anticipated benefits from the separation,
reliance on Recro and other third parties to provide certain
services post-separation, and the Company’s ability to satisfy
liabilities and potential indemnification obligations in connection
with the separation. The forward-looking statements in this press
release should be considered together with the risks and
uncertainties that may affect Baudax Bio’s business and future
results included in Baudax Bio’s filings with the Securities and
Exchange Commission at www.sec.gov.
CONTACT:
Investor Relations Contact: Argot PartnersSam
Martin / Claudia Styslinger(212) 600-1902sam@argotpartners.com
claudia@argotpartners.com
Baudax Bio Ryan D. Lake (484) 395-2436
rlake@baudaxbio.com
Media Contact: Argot Partners David Rosen (212)
600-1902 david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024